Date | Price Target | Rating | Analyst |
---|---|---|---|
11/20/2023 | $19.00 | Neutral | Goldman |
7/18/2023 | $44.00 | Outperform | William Blair |
5/18/2023 | Buy | Guggenheim | |
8/1/2022 | $40.00 | Overweight | Barclays |
12/21/2021 | $40.00 | Buy | HC Wainwright & Co. |
11/23/2021 | $55.00 | Outperform | Oppenheimer |
10/8/2021 | $50.00 → $65.00 | Strong Buy | Raymond James |
6/29/2021 | $39.00 → $50.00 | Strong Buy | Raymond James |
Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Generated $40.8 million in XDEMVY® net product sales in the second quarter and $65.5 million year-to-date Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an exceptional gross-to-net discount of 44% reflecting strong payer coverage including commercial and Medicare payers Expanded sales force remains on-track to be fully deployed by the end of the third quarter 2024 Management to host conference call today, August 8, 2024, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolut
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals
Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and remain on-track for broad commercial coverage by the end of 2024 and Medicare coverage beginning in 2025 Expanded sales force on-track to be in the field by the end of the third quarter 2024 Strengthened financial position with an approximately $108 million public equity offering and $200 million financing commitment Management to host conference call today, May 8, 2024, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDA
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Mr. Farrow succeeds Leo Greenstein who served as CFO since 2020 and will be leaving Tarsus to pursue other professional interests. Mr. Farrow is a seasoned finance and corporate strategy executive with more than two decades of experience successfully leading teams in the life science industry, including several publicly tra
Mr. Morrison brings over 40 years of financial and operational expertise in life sciences IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet patient needs, starting with eye care, through the application of proven science and new technology, today announced the appointment of Scott Morrison as Board Member and Audit Committee Chair. Mr. Morrison is a seasoned accounting and finance professional in the life sciences industry. He brings extensive expertise in corporate financing, pharmaceutical company operations, business development, and corporate governance. "We are pleased that Scott is joining the Board and s
PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brings the company's board of directors to eleven members. "We are excited to welcome an accomplished business leader with a proven track record of success join Certara's Board," said William F. Feehery, PhD, CEO of Certara. "Rose's experience in executive leadership and expertise in commercialization will provide immense value as the Company grows its impact on the biopharmaceutical industry worldwide." Ms. Crane has more than 35 years of experience in the ph
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $57 to $61.
Gainers Tevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INKT) stock increased by 31.09% to $1.18. The company's market cap stands at $40.9 million. Dynatronics (NASDAQ:DYNT) stock increased by 21.69% to $0.57. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out 2 days ago. Tarsus Pharmaceuticals (NASDAQ:TARS) shares moved upwards by 18.08% to $43.69. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q1 earnings report came out 3 days ago. CareCloud (NASDAQ:CCLD) shares
Barclays analyst Balaji Prasad maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and raises the price target from $50 to $60.
Goldman initiated coverage of Tarsus Pharmaceuticals with a rating of Neutral and set a new price target of $19.00
William Blair initiated coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $44.00
Guggenheim initiated coverage of Tarsus Pharmaceuticals with a rating of Buy
10-Q - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in Boston, MA, on Wednesday, September 4, at 11:15 a.m. PT / 2:15 p.m. ET. A live webcast and additional information about the presentation can be accessed on the events section of the Tar
Generated $40.8 million in XDEMVY® net product sales in the second quarter and $65.5 million year-to-date Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an exceptional gross-to-net discount of 44% reflecting strong payer coverage including commercial and Medicare payers Expanded sales force remains on-track to be fully deployed by the end of the third quarter 2024 Management to host conference call today, August 8, 2024, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolut
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals